-
公开(公告)号:US06518268B1
公开(公告)日:2003-02-11
申请号:US09608636
申请日:2000-06-30
申请人: Allison C. Chin , Ryan Holcomb , Mieczyslaw A. Piatyszek , Upinder Singh , Richard L. Tolman , Tsutomu Akama , Yutaka Kanda , Akira Asai , Yoshinori Yamashita , Kaori Endo , Hiroyuki Yamaguchi
发明人: Allison C. Chin , Ryan Holcomb , Mieczyslaw A. Piatyszek , Upinder Singh , Richard L. Tolman , Tsutomu Akama , Yutaka Kanda , Akira Asai , Yoshinori Yamashita , Kaori Endo , Hiroyuki Yamaguchi
IPC分类号: A61K31535
CPC分类号: A61K31/426 , A61K31/4439 , A61K31/506 , C07D277/34 , C07D277/36 , C07D417/06 , C07D417/10 , C07D513/04
摘要: Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are novel methods for assaying or screening for inhibitors of telomerase activity.
摘要翻译: 提供噻唑烷二酮化合物,组合物和在体外抑制端粒酶活性的方法以及离体和体内治疗端粒酶介导的病症或疾病。 本发明的方法,化合物和组合物可以单独使用或与其它药理学活性剂组合用于治疗由端粒酶活性介导的病症或疾病,例如治疗癌症。 还公开了用于测定或筛选端粒酶活性抑制剂的新方法。
-
公开(公告)号:US06869971B1
公开(公告)日:2005-03-22
申请号:US10110964
申请日:2000-10-19
申请人: Tsutomu Akama , Akira Asai , Tsutomu Agatsuma , Shinji Nara , Yoshinori Yamashita , Tamio Mizukami , Shun-ichi Ikeda , Yutaka Saitoh , Yutaka Kanda
发明人: Tsutomu Akama , Akira Asai , Tsutomu Agatsuma , Shinji Nara , Yoshinori Yamashita , Tamio Mizukami , Shun-ichi Ikeda , Yutaka Saitoh , Yutaka Kanda
IPC分类号: A61P31/04 , A61P35/00 , C07D487/04 , C07D487/14 , C07D487/16 , C07D491/14 , C07D491/147 , C07D491/16 , C07D498/08 , A61K31/403 , A61K31/4453 , C07D209/52 , C07D401/06
CPC分类号: C07D487/04 , C07D487/14 , C07D491/14
摘要: UCS 1025 derivatives having antitumor activity or antibacterial activity which are represented by formula (I): wherein R1 represents hydrogen, lower alkyl, etc.; R2 represents hydrogen, or is combined with R3 to represent a bond, etc., or is combined with R4 to represent —O(C═O)—, etc.; R3 represents hydrogen, etc., or is combined with R2 to represent a bond, etc.; R4 represents hydrogen, etc., or is combined with R2 to represent —(C═O)O—, etc.; R5 represents hydrogen or is combined with R6 to represent a bond; R6 represents hydrogen, etc., or is combined with R5 to represent a bond; R7 represents hydrogen or is combined with R8 to represent ═O; R8 represents hydroxy or is combined with R7 to represent ═O; ---- represents a single bond or a double bond, and a represents a single bond (two carbon atoms to which a is bound are combined to form a single bond) or an oxygen atom, or pharmaceutically acceptable salts thereof.
摘要翻译: 由式(I)表示的具有抗肿瘤活性或抗菌活性的UCS 1025衍生物:其中R 1表示氢,低级烷基等; R 2表示氢,或与R 3结合以表示键等,或与R 4结合以表示-O(C = O) - 等; R 3表示氢等,或与R 2结合以表示键等; R 4表示氢等,或与R 2结合代表 - (C = O)O-等; R 5表示氢或与R 6结合以表示键; R 6表示氢等,或与R 5结合以表示键; R 7表示氢或与R 8结合以代表= O; R 8表示羟基或与R 7结合代表= O; ----表示单键或双键,a表示单键(被结合形成单键的两个碳原子)或氧原子,或其药学上可接受的盐。
-
公开(公告)号:US5663298A
公开(公告)日:1997-09-02
申请号:US730348
申请日:1996-10-15
申请人: Tamio Mizukami , Akira Asai , Yoshinori Yamashita , Ritsuko Katahira , Atsuhiro Hasegawa , Keiko Ochiai , Shiro Akinaga
发明人: Tamio Mizukami , Akira Asai , Yoshinori Yamashita , Ritsuko Katahira , Atsuhiro Hasegawa , Keiko Ochiai , Shiro Akinaga
CPC分类号: C07K5/06026 , A61K38/00
摘要: The present invention relates to UCK14 compounds having antitumor activity which are represented by the formula: ##STR1## wherein R.sup.1 is hydrogen or --COOC(CH.sub.3).sub.3 ; and R.sup.2 and R.sup.3 are taken together to form --CH.sub.2 --, or each R.sup.2 and R.sup.3 independently are hydrogen,and pharmaceutically acceptable salts thereof.
摘要翻译: 本发明涉及具有抗肿瘤活性的UCK14化合物,其由下式表示:其中R 1为氢或-COOC(CH 3)3; 并且R 2和R 3一起形成-CH 2 - ,或每个R 2和R 3独立地是氢,及其药学上可接受的盐。
-
公开(公告)号:US5717110A
公开(公告)日:1998-02-10
申请号:US836314
申请日:1997-05-12
申请人: Tamio Mizukami , Akira Asai , Yoshinori Yamashita , Hirofumi Nakano , Shingo Kakita , Youichi Uosaki , Keiko Ochiai , Tadashi Ashizawa , Akira Mihara
发明人: Tamio Mizukami , Akira Asai , Yoshinori Yamashita , Hirofumi Nakano , Shingo Kakita , Youichi Uosaki , Keiko Ochiai , Tadashi Ashizawa , Akira Mihara
IPC分类号: C07D207/34 , C07D207/00
CPC分类号: C07D207/34
摘要: This invention relates to UCH15 compounds of the formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom or a hydroxyl group.
摘要翻译: PCT No.PCT / JP96 / 02587第 371日期:1997年5月12日 102(e)日期1997年5月12日PCT提交1996年9月11日PCT公布。 公开号WO97 / 10208 PCT 日本公开号为1997年3月20日本发明涉及式(I)的UCH15化合物:其中R 1表示氢原子或羟基。
-
公开(公告)号:US5798379A
公开(公告)日:1998-08-25
申请号:US994029
申请日:1997-12-18
申请人: Tamio Mizukami , Harumi Ogawa , Ryuichiro Nakai , Akira Asai , Yoshinori Yamashita , Katsuhiko Ando , Tsutomu Agatsuma , Shiro Akinaga , Kozo Ouchi , Hideki Kawasaki
发明人: Tamio Mizukami , Harumi Ogawa , Ryuichiro Nakai , Akira Asai , Yoshinori Yamashita , Katsuhiko Ando , Tsutomu Agatsuma , Shiro Akinaga , Kozo Ouchi , Hideki Kawasaki
IPC分类号: C07D487/04 , C07D491/16 , C12P17/14 , A61K31/40 , C07D487/02
CPC分类号: C07D487/04 , C12P17/14
摘要: UCS1025 compounds represented by the following formula (I): ##STR1## wherein R represents hydrogen or hydroxyl group, or tautomers or pharmacologically acceptable salts thereof.
摘要翻译: 由下式(I)表示的UCS1025化合物:其中R表示氢或羟基,或互变异构体或其药理学上可接受的盐。
-
公开(公告)号:US08796320B2
公开(公告)日:2014-08-05
申请号:US13519707
申请日:2010-12-28
申请人: Akira Asai , Kenji Matsuno , Naohisa Ogo , Osamu Takahashi , Yoshiaki Masuda , Ayumu Muroya , Yasuto Akiyama , Tadashi Ashizawa , Tadashi Okawara
发明人: Akira Asai , Kenji Matsuno , Naohisa Ogo , Osamu Takahashi , Yoshiaki Masuda , Ayumu Muroya , Yasuto Akiyama , Tadashi Ashizawa , Tadashi Okawara
IPC分类号: A61K31/4245 , C07D271/10 , C07D413/14
CPC分类号: C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04 , C07D513/04
摘要: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).
摘要翻译: 提供具有STAT3抑制活性并可用作抗癌剂的1,3,4-恶二唑-2-甲酰胺化合物。 提供由式(I)表示的1,3,4-恶二唑-2-甲酰胺化合物或其药学上可接受的盐(在该式中,Ar表示呋喃基等; R 1表示氢原子等; -X-Y表示二苯基等二芳基)。
-
公开(公告)号:US20080015828A1
公开(公告)日:2008-01-17
申请号:US11778367
申请日:2007-07-16
IPC分类号: G06F17/10
CPC分类号: G06F17/11
摘要: In an optimum design method comprising a first solution determining step of solving an optimization problem of a first evaluation function for a state variable vector with a design variable vector being as a parameter, and a second solution determining step of solving an optimization problem of a second evaluation function for the design variable vector and the state variable vector thus obtained, the second solution determining step includes the steps of computing a gradient vector of the second evaluation function for the design variable vector, computing a first coefficient based on a value of a norm of the gradient vector, computing a search vector based on the first coefficient, computing a second coefficient, and updating the design variable vector based on the second coefficient. The second coefficient computing step includes the first solution determining step, the first solution determining step is executed as an iterative method based on the gradient vector, and the state variable vector is not initialized during iteration. The optimum design method is precisely adaptable for structural changes.
摘要翻译: 一种最优设计方法,包括:第一解决方案确定步骤,用于以设计变量向量作为参数来求解用于状态变量向量的第一评估函数的优化问题;以及第二解决方案确定步骤,用于求解第二 第二解决方案确定步骤包括以下步骤:计算用于设计变量向量的第二评估函数的梯度向量,基于规范的值计算第一系数;对于设计变量向量和状态变量向量的评估函数, 的梯度向量,基于第一系数计算搜索向量,计算第二系数,并且基于第二系数更新设计变量向量。 第二系数计算步骤包括第一解决方案确定步骤,基于梯度向量作为迭代方法执行第一解决方案确定步骤,并且在迭代期间不初始化状态变量向量。 最佳设计方法适用于结构变化。
-
公开(公告)号:US07049198B2
公开(公告)日:2006-05-23
申请号:US10377771
申请日:2003-03-04
申请人: Koichiro Yuki , Tohru Saitoh , Minoru Kubo , Kiyoshi Ohnaka , Akira Asai , Koji Katayama
发明人: Koichiro Yuki , Tohru Saitoh , Minoru Kubo , Kiyoshi Ohnaka , Akira Asai , Koji Katayama
IPC分类号: H01L21/00
CPC分类号: H01L21/26506 , H01L21/2658 , H01L29/1054 , H01L29/165 , H01L29/167
摘要: An S1-yGey layer (where 0
摘要翻译: 按照此顺序形成S 1〜Y Ge层(其中0
-
公开(公告)号:US20050087803A1
公开(公告)日:2005-04-28
申请号:US10997127
申请日:2004-11-24
申请人: Yoshihiro Hara , Akira Asai , Gaku Sugahara , Haruyuki Sorada , Teruhito Ohnishi
发明人: Yoshihiro Hara , Akira Asai , Gaku Sugahara , Haruyuki Sorada , Teruhito Ohnishi
IPC分类号: H01L21/762 , H01L21/8234 , H01L29/10 , H01L27/01 , H01L27/12 , H01L29/06 , H01L29/76 , H01L31/062
CPC分类号: H01L29/1054 , H01L21/76224 , H01L21/823481 , Y10S438/933
摘要: On an Si substrate 1, a buffer layer 2, a SiGe layer 3, and an Si cap layer 4 are formed. A mask is formed on the substrate, and then the substrate is patterned. In this manner, a trench 7a is formed so as to reach the Si substrate 1 and have the side faces of the SiGe layer 3 exposed. Then, the surface of the trench 7a is subjected to heat treatment for one hour at 750° C. so that Ge contained in a surface portion of the SiGe layer 3 is evaporated. Thus, a Ge evaporated portion 8 having a lower Ge content than that of other part of the SiGe layer 3 is formed in part of the SiGe layer 3 exposed at part of the trench 7a. Thereafter, the walls of the trench 7a are oxidized.
摘要翻译: 在Si衬底1上形成缓冲层2,SiGe层3和Si覆盖层4。 在基板上形成掩模,然后对基板进行图案化。 以这种方式,形成沟槽7a以到达Si衬底1并且暴露SiGe层3的侧面。 然后,将沟槽7a的表面在750℃下进行1小时的热处理,使得包含在SiGe层3的表面部分中的Ge蒸发。 因此,在沟槽7a的一部分暴露的SiGe层3的一部分,形成Ge含量低于SiGe层3的Ge含量低的Ge蒸发部分8。 此后,沟槽7a的壁被氧化。
-
公开(公告)号:US06867107B2
公开(公告)日:2005-03-15
申请号:US10456531
申请日:2003-06-09
申请人: Akira Asai , Teruhito Ohnishi
发明人: Akira Asai , Teruhito Ohnishi
IPC分类号: H01L21/329 , H01L21/84 , H01L27/12 , H01L29/93 , H01L21/20
CPC分类号: H01L29/66174 , H01L21/84 , H01L27/1203 , H01L29/93
摘要: A variable capacitance device comprising, in a semiconductor layer formed on a substrate via an buried oxide film: an n− region 132 formed in the shape of a ring and containing an n-type dopant; an anode 133 adjoined to the outer periphery of the n− region 132, the anode 133 being formed in the shape of a ring and containing a p-type dopant; and a cathode 131 adjoined to the inner periphery of the n− region 132, the third region containing an n-type dopant, wherein the dopant concentration in the n− region 132 is lower than that in each of the anode 133 and the cathode 131.
摘要翻译: 一种可变静电电容器件,包括:通过掩埋氧化膜形成在衬底上的半导体层:形成为环形并包含n型掺杂剂的n区132; 邻接于n-区132的外周的阳极133,阳极133形成为环状并含有p型掺杂剂; 以及与n区132的内周相邻的阴极131,所述第三区包含n型掺杂剂,其中所述n区132中的掺杂剂浓度低于阳极133和阴极131中的掺杂浓度 。
-
-
-
-
-
-
-
-
-